CA2602290C - Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies - Google Patents

Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies Download PDF

Info

Publication number
CA2602290C
CA2602290C CA2602290A CA2602290A CA2602290C CA 2602290 C CA2602290 C CA 2602290C CA 2602290 A CA2602290 A CA 2602290A CA 2602290 A CA2602290 A CA 2602290A CA 2602290 C CA2602290 C CA 2602290C
Authority
CA
Canada
Prior art keywords
idebenone
cardiomyopathy
administration
pharmaceutical composition
muscular dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2602290A
Other languages
English (en)
French (fr)
Other versions
CA2602290A1 (en
Inventor
Thomas Meier
Gunnar Buyse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santhera Pharmaceuticals Schweiz GmbH
Original Assignee
Santhera Pharmaceuticals Schweiz GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36572153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2602290(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santhera Pharmaceuticals Schweiz GmbH filed Critical Santhera Pharmaceuticals Schweiz GmbH
Publication of CA2602290A1 publication Critical patent/CA2602290A1/en
Application granted granted Critical
Publication of CA2602290C publication Critical patent/CA2602290C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2602290A 2005-03-21 2006-03-20 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies Expired - Fee Related CA2602290C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05006137.3 2005-03-21
EP05006137 2005-03-21
PCT/EP2006/002536 WO2006100017A1 (en) 2005-03-21 2006-03-20 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies

Publications (2)

Publication Number Publication Date
CA2602290A1 CA2602290A1 (en) 2006-09-28
CA2602290C true CA2602290C (en) 2012-01-17

Family

ID=36572153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2602290A Expired - Fee Related CA2602290C (en) 2005-03-21 2006-03-20 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies

Country Status (17)

Country Link
US (1) US7977388B2 (https=)
EP (1) EP1861080B1 (https=)
JP (1) JP4896123B2 (https=)
AT (1) ATE468849T1 (https=)
AU (1) AU2006226623B2 (https=)
CA (1) CA2602290C (https=)
CY (1) CY1110182T1 (https=)
DE (1) DE602006014514D1 (https=)
DK (1) DK1861080T3 (https=)
ES (1) ES2345353T3 (https=)
MX (1) MX2007011571A (https=)
NZ (1) NZ561235A (https=)
PL (1) PL1861080T3 (https=)
PT (1) PT1861080E (https=)
SI (1) SI1861080T1 (https=)
WO (1) WO2006100017A1 (https=)
ZA (1) ZA200707833B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103271935A (zh) 2006-08-01 2013-09-04 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
EP1891946A1 (en) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
WO2009079562A2 (en) 2007-12-17 2009-06-25 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
SI2108366T1 (sl) * 2008-04-09 2012-01-31 Santhera Pharmaceuticals Ch Idebenon za zdravljenje respiratorne bolezni pri miĺ iäśni distrofiji
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
DK2605769T3 (en) 2010-08-16 2016-10-24 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinonderivater for the treatment of mitochondrial diseases of the eye
CN103086861B (zh) * 2012-11-12 2015-09-16 刘炜 羟癸基苯醌衍生物及其用途
US20230047313A1 (en) * 2019-12-16 2023-02-16 Children`S Medical Center Corporation Treating heart disease in muscular dystrophy patients
EP4351545A1 (en) 2021-06-07 2024-04-17 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy
CN113827585B (zh) * 2021-10-27 2023-04-11 山东大学齐鲁医院 艾地苯在治疗肢带型肌营养不良2g型中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562998A (en) 1997-08-12 1999-03-01 Takeda Chemical Industries Ltd. Idebenone-containing preparation for percutaneous administration
JPH11116470A (ja) 1997-08-12 1999-04-27 Takeda Chem Ind Ltd イデベノン含有経皮投与製剤
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US20040081961A1 (en) * 2001-05-04 2004-04-29 Delegeane Angelo M Proteases
EP1618881A1 (en) 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy

Also Published As

Publication number Publication date
DE602006014514D1 (https=) 2010-07-08
AU2006226623B2 (en) 2010-04-22
WO2006100017A1 (en) 2006-09-28
PL1861080T3 (pl) 2010-10-29
ATE468849T1 (de) 2010-06-15
PT1861080E (pt) 2010-06-17
SI1861080T1 (sl) 2010-08-31
MX2007011571A (es) 2007-12-06
JP2008533182A (ja) 2008-08-21
CY1110182T1 (el) 2015-01-14
US20090012050A1 (en) 2009-01-08
EP1861080B1 (en) 2010-05-26
US7977388B2 (en) 2011-07-12
NZ561235A (en) 2010-12-24
EP1861080A1 (en) 2007-12-05
CA2602290A1 (en) 2006-09-28
DK1861080T3 (da) 2010-09-06
ES2345353T3 (es) 2010-09-21
JP4896123B2 (ja) 2012-03-14
AU2006226623A1 (en) 2006-09-28
ZA200707833B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
US11771683B2 (en) Dosing regimen for a selective S1P1 receptor agonist
EP4370116B1 (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
CA2602290C (en) Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies
CA2719440C (en) Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy
JP2022512765A (ja) 神経疾患の処置
US20240148735A1 (en) Methods of treating heart failure with vibegron
US20200306222A1 (en) Dosing Regimen of Siponimod
US12419863B2 (en) Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
US7875648B2 (en) N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
KR19990023705A (ko) 심부전증 치료용 약학 조성물
Baati et al. Alteration of skeletal and cardiac muscles function in DBA/2J mdx mice background: a focus on high intensity interval training
JP2023521708A (ja) 肥大型心筋症治療用薬学組成物およびその組成物を用いた治療方法
CN116966276A (zh) Kdm5a在制备治疗心梗后心肌纤维化药物中的应用
HK1142607B (en) Thiazolium salt compound and use of treating disease related with protein aging
HK1142607A1 (en) Thiazolium salt compound and use of treating disease related with protein aging

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220321